The Drug Enforcement Administration has raised the production limits for Takeda Pharmaceutical's attention-deficit/hyperactivity disorder drug Vyvanse, or lisdexamfetamine, and its generic versions by approximately 24% to address the short supply of the drug. "These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally," the agency said.